{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-008697","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.831831+00:00","generated_at":"2026-06-07T16:12:11.424132+00:00","sec_items":["5.07"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Odyssey Health shareholders approve asset sale of neurological drug therapies to Oragenics","bullets":["Approved asset purchase agreement of neurological drug therapies and technologies to Oragenics, Inc.","Vote: 45,032,700 for, 333,249 against, 48,943 abstaining on the asset purchase agreement.","Approved adjournment proposal: 44,826,263 for, 255,690 against, 332,939 abstaining.","Special meeting held on December 7, 2023; results filed via 8-K Item 5.07."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-008697","json":"https://secwatch.observer/filing/0001683168-23-008697.json","markdown":"https://secwatch.observer/filing/0001683168-23-008697.md","text":"https://secwatch.observer/filing/0001683168-23-008697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823008697/0001683168-23-008697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823008697/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:12:11.424132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba4fea5fbe7b727a5f577685555142f2e1c8c57b","claim":"Odyssey Health, Inc. shareholders approved Approval of the asset purchase agreement of its neurological drug therapies and technologies to Oragenics, Inc. (reported as Oragenics in context? Actually the text says \"Odyssey Health, Inc. formerly known as Odyssey Group International, Inc. (“Odyssey”) held its Special Meeting of Stockholders. At at the 2023-12-07 meeting.","evidence_excerpt":"(1) approved the asset purchase agreement of its neurological drug therapies and technologies to Oragenics, Inc.;","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823008697/0001683168-23-008697-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"merger approval"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"},{"claim_id":"bb6825c6638a77cabaf50e7731defc3a5ed2146c","claim":"Odyssey Health, Inc. shareholders approved Approval of adjournment or postponement of the Special Meeting, if necessary at the 2023-12-07 meeting.","evidence_excerpt":"(2) approved the adjournment or postponement of the Special Meeting, if necessary.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823008697/0001683168-23-008697-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-12-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}